MA52118A - Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose - Google Patents

Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose

Info

Publication number
MA52118A
MA52118A MA052118A MA52118A MA52118A MA 52118 A MA52118 A MA 52118A MA 052118 A MA052118 A MA 052118A MA 52118 A MA52118 A MA 52118A MA 52118 A MA52118 A MA 52118A
Authority
MA
Morocco
Prior art keywords
fibrosis
treatment
pharmaceutical compositions
new compounds
compounds
Prior art date
Application number
MA052118A
Other languages
English (en)
Inventor
Brigitte Allart
Franck Laurent Brebion
Béranger Duthion
Bkassiny Sandy El
Koen Karel Jansen
Alexis Patrick Claude Jaunet
Oscar Mammoliti
Christel Jeanne Marie Menet
Adeline Marie Elise Palisse
Giovanni Alessandro Tricarico
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA52118A publication Critical patent/MA52118A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052118A 2017-07-06 2018-06-21 Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose MA52118A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1710851.5A GB201710851D0 (en) 2017-07-06 2017-07-06 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
MA52118A true MA52118A (fr) 2021-05-19

Family

ID=59676764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052118A MA52118A (fr) 2017-07-06 2018-06-21 Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose

Country Status (18)

Country Link
US (1) US20210315893A1 (fr)
EP (1) EP3649119B1 (fr)
JP (1) JP2020525508A (fr)
KR (1) KR20200027543A (fr)
CN (1) CN110869359A (fr)
AR (1) AR112264A1 (fr)
AU (1) AU2018296398A1 (fr)
BR (1) BR112020000029A2 (fr)
CA (1) CA3069038A1 (fr)
CO (1) CO2020000056A2 (fr)
GB (1) GB201710851D0 (fr)
IL (1) IL271807A (fr)
MA (1) MA52118A (fr)
MX (1) MX2019015350A (fr)
RU (1) RU2020105248A (fr)
SG (1) SG11202000032PA (fr)
TW (1) TW201920167A (fr)
WO (1) WO2019007696A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
WO2019175897A1 (fr) 2018-03-13 2019-09-19 Jubilant Biosys Limited Composés bicycliques utilisés en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1
US20220233545A1 (en) * 2019-06-21 2022-07-28 Dana-Farber Cancer Institute, Inc. Allosteric egfr inhibitors and methods of use thereof
WO2021175223A1 (fr) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 Composé benzo 2-azaspiro[4,4]nonane et son utilisation
MX2023001757A (es) * 2020-08-14 2023-02-22 Denali Therapeutics Inc Compuestos, composiciones y metodos.
EP3974415A1 (fr) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nouveaux composés
CN113234024A (zh) * 2021-05-20 2021-08-10 北京迈索化学技术有限公司 一种奥拉帕利的制备新方法
CN113929689B (zh) * 2021-11-02 2022-09-27 济南悟通生物科技有限公司 一种鲁卡帕利关键中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
EP2132186A1 (fr) * 2007-03-06 2009-12-16 Novartis AG Composés organiques bicycliques adaptés au traitement des états inflammatoires ou allergiques
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010047990A1 (fr) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Modulateurs de récepteur m1 allostériques positifs hétérocycliques condensés
NZ598220A (en) * 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
ES2593256T3 (es) * 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
ES2650744T3 (es) * 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
WO2013032591A1 (fr) * 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Composés hétérocycliques et leurs utilisations
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2020009849A (es) * 2012-11-01 2021-09-13 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
UY35332A (es) * 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
PT3269716T (pt) 2013-03-14 2020-10-09 Galapagos Nv Novos compostos e suas composições farmacêuticas para o tratamento de doenças inflamatórias

Also Published As

Publication number Publication date
AR112264A1 (es) 2019-10-09
US20210315893A1 (en) 2021-10-14
GB201710851D0 (en) 2017-08-23
WO2019007696A1 (fr) 2019-01-10
CA3069038A1 (fr) 2019-01-10
BR112020000029A2 (pt) 2020-07-14
MX2019015350A (es) 2020-02-20
EP3649119B1 (fr) 2021-11-03
KR20200027543A (ko) 2020-03-12
SG11202000032PA (en) 2020-02-27
RU2020105248A (ru) 2021-08-06
IL271807A (en) 2020-02-27
CO2020000056A2 (es) 2020-01-17
EP3649119A1 (fr) 2020-05-13
AU2018296398A1 (en) 2020-02-27
JP2020525508A (ja) 2020-08-27
CN110869359A (zh) 2020-03-06
TW201920167A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
LU92577B1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA52421A (fr) Composés pharmaceutiques
LU92578B1 (fr) Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA50205A (fr) Formulation de nicotine
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA49837A (fr) Compositions pharmaceutiques
MA55015A (fr) Formulations pharmaceutiques
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA52960A (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose
MA50526A (fr) Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA42552A (fr) Compositions pharmaceutiques de flurbiprofène et de tramadol
MA41432A (fr) Composition pharmaceutique pour le traitement de maladies gastro-intestinales
MA49625A (fr) Compositions pharmaceutiques